NCT06222437

Semaglutide and Polycystic Ovarian Syndrome: an Emerging Treatment Strategy

• Status: Withdrawn
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 0 (actual)
• Sponsor: Methodist Health System · Academic / Other
• Sex: Female
• Age: 18 Years – 45 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this study is to investigate the effect of semaglutide in women with Polycystic Ovarian Syndrome(PCOS ) and determine potential therapeutic benefits.

Detailed description

The study mainly focused for the following objectives: To determine the effect of semaglutide on ovulation and menstrual regularity. To determine the effect of semaglutide on androgen levels, namely testosterone, sex hormone binding globulin, and changes in hirsutism. To determine changes in weight, body mass index (BMI), and Glycated Hemoglobin( HbA1c) with semaglutide therapy.

Conditions

• Polycystic Ovary Syndrome

Interventions

Type	Name	Description
DRUG	Semaglutide	effectiveness of semaglutide in PCOS

Timeline

• Start date: 2026-02-01
• Primary completion: 2026-02-01
• Completion: 2027-02-01
• First posted: 2024-01-24
• Last updated: 2026-03-23

Regulatory

• FDA-regulated drug study